PL2292625T3 - Podstawione spiro-związki i ich zastosowanie do wytwarzania przeciwbólowych środków leczniczych - Google Patents

Podstawione spiro-związki i ich zastosowanie do wytwarzania przeciwbólowych środków leczniczych

Info

Publication number
PL2292625T3
PL2292625T3 PL10012043T PL10012043T PL2292625T3 PL 2292625 T3 PL2292625 T3 PL 2292625T3 PL 10012043 T PL10012043 T PL 10012043T PL 10012043 T PL10012043 T PL 10012043T PL 2292625 T3 PL2292625 T3 PL 2292625T3
Authority
PL
Poland
Prior art keywords
aliphatic compound
gen
optionally substituted
cycloaliphatic group
diastereomer
Prior art date
Application number
PL10012043T
Other languages
English (en)
Inventor
Robert Frank
Melanie Reich
Ruth Jostock
Gregor Bahrenberg
Fritz Theil
Brigitta Henkel
Hans Schick
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of PL2292625T3 publication Critical patent/PL2292625T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10012043T 2005-05-19 2006-05-17 Podstawione spiro-związki i ich zastosowanie do wytwarzania przeciwbólowych środków leczniczych PL2292625T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005023784A DE102005023784A1 (de) 2005-05-19 2005-05-19 Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
EP10012043.5A EP2292625B1 (de) 2005-05-19 2006-05-17 Substituierte spiro-verbindungen und deren verwendung zur herstellung von arzneimitteln gegen schmerz
EP06742950A EP1893620B1 (de) 2005-05-19 2006-05-17 Substituierte spiro-verbindungen und deren verwendung zur herstellung von arzneimitteln gegen schmerz

Publications (1)

Publication Number Publication Date
PL2292625T3 true PL2292625T3 (pl) 2014-04-30

Family

ID=36646208

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10012043T PL2292625T3 (pl) 2005-05-19 2006-05-17 Podstawione spiro-związki i ich zastosowanie do wytwarzania przeciwbólowych środków leczniczych
PL06742950T PL1893620T3 (pl) 2005-05-19 2006-05-17 Podstawione spiro-związki i ich zastosowanie do wytwarzania przeciwbólowych środków leczniczych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL06742950T PL1893620T3 (pl) 2005-05-19 2006-05-17 Podstawione spiro-związki i ich zastosowanie do wytwarzania przeciwbólowych środków leczniczych

Country Status (13)

Country Link
US (1) US20080214807A1 (pl)
EP (2) EP2292625B1 (pl)
JP (1) JP5376941B2 (pl)
AT (1) ATE524478T1 (pl)
CA (1) CA2608385A1 (pl)
CY (1) CY1112137T1 (pl)
DE (1) DE102005023784A1 (pl)
DK (1) DK1893620T3 (pl)
ES (2) ES2447815T3 (pl)
PL (2) PL2292625T3 (pl)
PT (1) PT1893620E (pl)
SI (1) SI1893620T1 (pl)
WO (1) WO2006122769A2 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005044813A1 (de) 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
EP2064187A2 (en) * 2006-08-25 2009-06-03 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
CA2716128A1 (en) 2008-02-27 2009-09-03 Vitae Pharmaceuticals, Inc. Inhibitors of 11.beta.-hydroxysteroid dehydrogenase type 1
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8765735B2 (en) * 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
WO2011095450A1 (en) 2010-02-02 2011-08-11 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
AR107434A1 (es) 2016-01-13 2018-05-02 Gruenenthal Gmbh Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
HUE051642T2 (hu) 2016-01-13 2021-03-01 Gruenenthal Gmbh 8-amino-2-oxo-1,3-diaza-spiro-[4,5]-dekán származékok
WO2017121649A1 (en) 2016-01-13 2017-07-20 Grünenthal GmbH 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001527513A (ja) * 1996-03-15 2001-12-25 デュポン ファーマシューティカルズ カンパニー スピロ環インテグリン阻害剤
WO1998043962A1 (en) * 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
ES2322723T5 (es) * 1998-05-08 2013-03-11 The Regents Of The University Of California Métodos para detectar e inhibir la angiogénesis
DE10130020A1 (de) * 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
EP1506166B1 (en) * 2002-05-17 2011-11-16 Janssen Pharmaceutica NV Aminotetralin-derived urea modulators of vanilloid vr1 receptor
ATE493987T1 (de) * 2002-05-22 2011-01-15 Amgen Inc Aminopyrimidin-derivate zur verwendung als vanilloid-rezeptor-liganden zur behandlung von schmerzen
DE102004032567A1 (de) * 2004-07-05 2006-03-02 Grünenthal GmbH Substituierte 1-Propiolyl-piperazine

Also Published As

Publication number Publication date
DK1893620T3 (da) 2012-01-16
WO2006122769A2 (de) 2006-11-23
EP1893620A2 (de) 2008-03-05
ES2447815T3 (es) 2014-03-13
US20080214807A1 (en) 2008-09-04
ATE524478T1 (de) 2011-09-15
EP2292625B1 (de) 2013-12-25
JP5376941B2 (ja) 2013-12-25
DE102005023784A1 (de) 2006-11-30
PT1893620E (pt) 2011-10-31
WO2006122769A3 (de) 2007-03-15
SI1893620T1 (sl) 2012-04-30
EP2292625A1 (de) 2011-03-09
CA2608385A1 (en) 2006-11-23
CY1112137T1 (el) 2015-11-04
EP1893620B1 (de) 2011-09-14
ES2370038T3 (es) 2011-12-12
PL1893620T3 (pl) 2012-02-29
JP2008540592A (ja) 2008-11-20

Similar Documents

Publication Publication Date Title
PL2292625T3 (pl) Podstawione spiro-związki i ich zastosowanie do wytwarzania przeciwbólowych środków leczniczych
AU2011215704B2 (en) Secondary structure stabilized NMDA receptor modulators and uses thereof
PT1599167E (pt) Derivados de benzimidazole e de imidazo-piridina, tendo uma afinidade para os receptores das melanocortinas e a sua utilização como medicamento
WO2007091948A3 (en) Novel spiro [imidazolidine-4, 3´-indole] 2, 2´,5´(1h) triones for treatment of conditions associated with vanilloid receptor 1
CA2523261A1 (en) Fused pyrimidine derivatives with crf activity
WO2004014902A3 (en) Compounds having an activity at metabotropic glutamate receptors
EA200400762A1 (ru) Новые соединения, их использование в медицине, способ их изготовления и содержащие их фармацевтические композиции
MY138086A (en) Novel urea derivative as vanilloid receptor-1 antagonist
EP2331571A1 (en) Nmda receptor modulators and uses thereof
SE9904508D0 (sv) New compounds
PL1910381T3 (pl) Podstawione związki 1-oksa-3,8-diazaspiro[4.5]dekan-2-onowe i ich zastosowanie do wytwarzania środków leczniczych
MXPA02011053A (es) Compuestos novedosos de carboxi amino espiro (2,4)heptano y derivados de los mismos.
SE0102055D0 (sv) New Compounds
Wrobleski et al. Cyclobutane derivatives as potent NK1 selective antagonists
MXPA04005426A (es) Derivados de pirazol de anillos fuisionados.
MXPA05008186A (es) Derivados de quinoxalina saturados y su uso como ligandos receptores de glutamato metabotropico.
CA2490115A1 (en) Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
PL1968957T3 (pl) Podstawione tiazole i ich zastosowanie do wytwarzania środków leczniczych
HK1074630A1 (en) Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
Liu et al. A mild and efficient synthesis of monofluorinated α-lactam pseudopeptides via a novel dehydrofluorination of Ugi products
SG146692A1 (en) Melanin concentrating hormone antagonists
RU94032285A (ru) Цефалоспориновые соединения, способ их получения, фармацевтическая композиция
NZ544481A (en) norgestrel 3e- and -3z-oxime isomers, as well as process for the synthesis of the mixture of isomers and the pure isomers
EA015500B9 (ru) Новые антагонисты мсн рецепторов
US20120309811A1 (en) P-glycoprotein-specific non-competitive peptide and peptidomimetic modulators